Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)

Mahdee Sobhanie, Yumiko Matsuoka, Sinthujan Jegaskanda, Theresa Fitzgerald, Raburn Mallory, Zhongying Chen, Catherine Luke, John Treanor, Kanta Subbarao, Mahdee Sobhanie, Yumiko Matsuoka, Sinthujan Jegaskanda, Theresa Fitzgerald, Raburn Mallory, Zhongying Chen, Catherine Luke, John Treanor, Kanta Subbarao

Abstract

Background: We evaluated a candidate A/Anhui/2013(H7N9) pandemic live attenuated influenza vaccine (pLAIV) in healthy adults, and assessed the ability of 1 or 2 doses to induce immune memory.

Methods: Healthy subjects in 2 age groups (18-49 years and 50-70 years) with undetectable hemagglutination-inhibiting (HAI) antibody to H7N9 were enrolled. Younger subjects received either 1 or 2 intranasal doses of 10(7.0) fluorescent focus units of A/Anhui/1/2013 pLAIV, while older subjects received a single dose. All subjects received a single 30-µg dose of unadjuvanted, antigenically matched A/Shanghai2/2013(H7N9) pandemic inactivated influenza vaccine (pIIV) 12 weeks after their first dose of pLAIV.

Results: Both vaccines were well tolerated. Serum HAI antibody responses were detected in 0 of 32 younger subjects and 1 of 17 older subjects after 1 dose of pLAIV and in 2 of 16 younger subjects after a second dose. Strong serum antibody responses were detected after a single subsequent dose of pIIV that was broadly reactive against H7 influenza viruses.

Conclusions: An A(H7N9) pLAIV candidate was safe in both age groups. Priming with pLAIV resulted in responses to subsequent pIIV that exceeded those seen in naive subjects in previous reports. The A(H7N9) pLAIV induces strong immune memory that can be demonstrated by exposure to subsequent antigenic challenge.

Clinical trials registration: NCT01995695 and NCT02274545.

Keywords: immune memory; live vaccine; pandemic influenza.

© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Kinetics of the serum antibody response to a single dose of unadjuvanted A(H7N9) inactivated influenza vaccine (IIV) in younger subjects who previously received 1 dose (diamonds, dashed lines) or 2 doses (squares, solid lines), or older subjects (circles, dotted lines) who received 1 dose of A(H7N9) live attenuated influenza vaccine (LAIV). Data are for subjects considered responders by that specific test. A, Results of the hemagglutination-inhibition assay, using the A(H7N9) LAIV and horse red blood cells. B, Results of the microneutralization assay, using the A(H7N9) LAIV. C, Results of the immunoglobulin G–specific enzyme-linked immunosorbent assay (ELISA), using baculovirus-expressed A/Anhui/1/13(H7N9) hemagglutinin. D, Results of the immunoglobulin A–specific ELISA, using baculovirus-expressed A/Anhui/1/13(H7N9) hemagglutinin. ELISA was only performed on sera obtained from younger subjects. Abbreviation: GMT, geometric mean titer.
Figure 2.
Figure 2.
Neutralizing antibody titers against wild-type influenza A(H7N9) viruses. Sera collected 28 days after inactivated influenza vaccine boost in younger recipients of 1 (left) or 2 (right) doses of live attenuated influenza vaccine priming were tested by microneutralization (MN) assay against the following wild-type H7 influenza viruses under biosafety level 3 conditions: A/Anhui/1/2013 (H7N9, human; A), A/Hong Kong/734/2014 (H7N9, human; B), A/Netherlands/219/2003 (H7N7, human; C), A/ck/British Columbia/CN-7/2004 (H7N3, avian; D). Data are shown for sera that had a titer of ≥1:32 against the homologous influenza A/Anhui/1/2013 virus. The solid bar represents the mean.
Figure 3.
Figure 3.
Induction of A(H7N9)-specific antibody-dependent cellular cytotoxicity (ADCC) following a pandemic live attenuated influenza vaccine (pLAIV) and pandemic inactivated influenza vaccine (pIIV) regimen. ADCC titer to rH7 hemagglutinin (A/Anhui/01/2013) in serum obtained from younger subjects at day 0 and day 28 following receipt of either 1 dose (n = 14) or 2 doses (n = 16) of A(H7N9) pLAIV (A and B) and following receipt of an A(H7N9) pIIV boost (C and D). The line indicates the geometric mean value for the group. *P < .05, by the Student t test.

References

    1. Gao H-N, Lu H-Z, Cao B et al. . Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277–85.
    1. Ai J, Huang Y, Xu K et al. . Case-control study of risk factors for human infection with influenza A(H7N9) virus in Jiangsu province, China, 2013. Euro Surveillance 2013; 18:20510.
    1. Wang C, Yu H, Horby PW et al. . Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis 2014; 58:1095–103.
    1. Mulligan MJ, Bernstein DI, Winokur PL et al. . Serological responses for an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 2014; 312:1409–19.
    1. Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesa-thasan N. A cell culture–derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014; 6:234ra55.
    1. Belshe RB, Edwards KM, Vesikari T et al. . Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685–96.
    1. Ashkenazi S, Vertruyen A, Aristegui J et al. . Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870–9.
    1. Fleming DM, Crovari P, Wahn U et al. . Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860–9.
    1. Karron RA, Talaat K, Luke C et al. . Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009; 27:4953–60.
    1. Talaat KR, Karron RA, Luke CJ et al. . An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011; 29:3144–8.
    1. Talaat KR, Karron RA, Liang PH et al. . An open-label, phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses 2013; 7:66–73.
    1. Talaat KR, Karron RA, Callahan KA et al. . A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009; 27:3744–53.
    1. Talaat KR, Luke CJ, Khurana S et al. . A live attenuated influenza A (H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014; 209:1860–9.
    1. Babu T, Levine M, Fitzgerald T et al. . Live attenuated H7N7 influenza vaccine primes for a vigorous antibdy response to inactivated H7N7 influenza vaccine. Vaccine 2014; 32:6798–804.
    1. Chen Z, Baz M, Lu J et al. . Development of a high yield live attenuated H7N9 influenza vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol 2014; 88:7016–23.
    1. Lorbetskie B, Wang J, Gravel C et al. . Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 2011; 29:3377–89.
    1. Karron Ruth A, Callahan K, Luke C et al. . A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009; 199:711–6.
    1. Shu B, Wu KH, Emery S et al. . Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus. J Clin Microbiol 2011; 49:2614–9.
    1. Jin H, Lu B, Zhou H et al. . Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003; 306:18–24.
    1. Rowe T, Abernathy RA, Hu-Primmer J et al. . Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937–43.
    1. Jegaskanda S, Job ER, Kramski M et al. . Cross-reactive influenzaq-specific antibody-dependent cellular cytotoxicity antibodies i the absence of neutralizing antibodies. J Immunol 2013; 190:1837–48.
    1. Jegaskanda S, Vandenberg K, Laurie K et al. . Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J Infect Dis 2014; 201:1811–22.
    1. Ledgerwood JE, Wei C-J, Hu Z et al. . DNA priming and influenza vaccine immunogenicity: two phase I open label randomised clinical trials. Lancet Infect Dis 2011; 11:916–24.
    1. Ledgerwood JE, Zephir K, Hu Z et al. . Prime-boost interval matters: A randomized phase I study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013; 354:418–22.
    1. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc[gamma]R interactions for protection against influenza virus in vivo. Nat Med 2014; 20:143–51.
    1. Corti D, Voss J, Gamblin SJ et al. . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850–6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe